StockUS listing USSPRONASDAQHealthcareBalanced

Spero Therapeutics Inc(SPRO) Stock Analysis | Healthcare

USD --+0.00%
Reward61Moderate
Risk59Medium-High
75%Data
Strong 16% profit margin · Revenue down 96% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 58.26M
Reward Ratingⓘ61 Moderate reward assessment · 75% data coverage
Top 50% of stocksView factors
Risk Ratingⓘ59 Medium-High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on SPRO to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Spero Therapeutics Inc?

, a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.

AI Brief Pro

The brief on Spero Therapeutics Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Spero Therapeutics Inc?

, a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 58.26M.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (61)
Company Information
SectorHealthcare
IndustryBiotechnology
Beta1.564
Insider Activity
12M windowQuiet
Fewer than three real open-market insider trades in the last 12 months. Mechanical activity (option exercises, RSU vests) is excluded from the signal.